Oxidized LDL regulates efferocytosis through the CD36-PKM2-mtROS pathway
Jue Zhang,Jackie Chang,Vaya Chen,Mirza Ahmar Beg,Wenxin Huang,Lance Vick,Yaxin Wang,Heng Zhang,Erin Yttre,Ankan Gupta,Mark Castleberry,Ziyu Zhang,Wen Dai,Shan Song,Jieqing Zhu,Moua Yang,Ashley Kaye Brown,Zhen Xu,Yan-qing Ma,Brian Christopher Smith,Jacek Zielonka,James G Taylor Jr.,Cyrine Ben Dhaou,Anthony Wayne Orr,Weiguo Cui,Ze Zheng,Yiliang Chen
DOI: https://doi.org/10.1101/2023.09.07.556574
2024-07-15
Abstract:Macrophage efferocytosis, the process by which phagocytes engulf and remove apoptotic cells (ACs), plays a critical role in maintaining tissue homeostasis. Efficient efferocytosis prevents secondary necrosis, mitigates chronic inflammation, and impedes atherosclerosis progression. However, the regulatory mechanisms of efferocytosis under atherogenic conditions remain poorly understood. We previously demonstrated that oxidized LDL (oxLDL), an atherogenic lipoprotein, induces mitochondrial reactive oxygen species (mtROS) in macrophages via CD36. In this study, we demonstrate that macrophage mtROS facilitate continual efferocytosis through a positive feedback mechanism. However, oxLDL disrupts continual efferocytosis by dysregulating the internalization of ACs. This disruption is mediated by an overproduction of mtROS. Mechanistically, oxLDL/CD36 signaling promotes the translocation of cytosolic PKM2 to mitochondria, facilitated by the chaperone GRP75. Mitochondrial PKM2 then binds to Complex III of the electron transport chain, inducing mtROS production. This study elucidates a novel regulatory mechanism of efferocytosis in atherosclerosis, providing potential therapeutic targets for intervention.
Immunology